Lymphoid enhancer binding factor-1 (LEF1) expression as a prognostic factor in adult acute promyelocytic leukemia
Metrics: PDF 2096 views | HTML 2149 views | ?
Francesco Albano1, Antonella Zagaria1, Luisa Anelli1, Paola Orsini1, Crescenzio Francesco Minervini1, Luciana Impera1, Paola Casieri1, Nicoletta Coccaro1, Giuseppina Tota1, Claudia Brunetti1, Angela Minervini1, Domenico Pastore1, Paola Carluccio1, Anna Mestice1, Angelo Cellamare1, and Giorgina Specchia1
1 Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, Bari, Italy.
Francesco Albano, email:
Keywords: acute promyelocytic leukemia, LEF1; prognosis; outcome.
Received: November 20, 2013 Accepted: December 19, 2013 Published: December 19, 2013
Lymphoid enhancer-binding factor 1 (LEF1) is a downstream effector of the Wnt/ β-catenin signaling pathway. High LEF1 expression has been reported as a prognostic marker in hematologic malignancies. We evaluated the prognostic significance of LEF1 expression in 78 adult acute promyelocytic leukemia (APL) patients. APL samples were dichotomized at the median value and divided into: LEF1low and LEF1high. LEF1highpatients had lower WBC counts at baseline and were less likely to carry a FLT3-ITD than LEF1low patients. Early death occurred only in the LEF1low group. Moreover, LEF1low expression was associated with a high Sanz score. Survival analysis of 61 APL patients < 60 years revealed that the LEF1high group had a significantly longer overall survival (OS). Cox analysis for OS confirmed only LEF1 expression as an independent prognostic factor. Of the 17 patients over the age of 60, those in the LEF1high group showed a higher median survival. In silico analysis identified 9 differentially expressed, up-modulated genes associated with a high expression of LEF1; the majority of these genes is involved in the regulation of apoptosis. Our study provides evidence that LEF1 expression is an independent prognostic factor in APL, and could be used in patients risk stratification.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.